20
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2119 |
Venetoclax
GDC-0199,ABT 199,维奈妥拉,ABT-199,ABT199 |
BCL; Autophagy | Apoptosis; Autophagy |
Venetoclax (ABT-199) 是一种 Bcl-2 抑制剂 (Ki<0.01 nM),具有高效性、选择性和口服活性。Venetoclax 与 Bcl-xL 和 Bcl-W 的亲和力降低了 3 个数量级(Kis=48/245 nM)。Venetoclax 可以诱导自噬和凋亡。 | |||
T2101 |
Navitoclax
ABT-263 |
BCL | Apoptosis |
Navitoclax (ABT-263) 是一种 Bcl-2 抑制剂,可与 Bcl-xL、Bcl-2、Bcl-w 等蛋白结合 (Ki<1 nM),具有有效性和口服活性。Navitoclax 具有抗肿瘤活性,可以诱导细胞凋亡。 | |||
T12186 |
Navitoclax-piperazine
ABT-263-piperazine |
BCL; Ligands for Target Protein for PROTAC | Apoptosis; PROTAC |
Navitoclax-piperazine (ABT-263-piperazine) 是一种特大型 B 细胞淋巴瘤(BCL-XL)抑制剂。它和 E3 泛素连接酶的 VHL 配体可用来合成 PROTAC DT2216。 | |||
T11944 |
Maritoclax
Marinopyrrole A |
BCL | Apoptosis |
Maritoclax (Marinopyrrole A) 是一种新型特异性 Mcl-1 抑制剂,IC50值为 10.1 μM,对 BCL-xl 的 IC50值 > 80 μM。 | |||
T10483 |
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1,APG-2575 |
BCL | Apoptosis |
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) 是一种双重 Bcl-2 和 Bcl-xl 抑制剂(IC50:2 nM 和 5.9 nM),具有抗肿瘤活性。 | |||
T6650 |
Sabutoclax
BI-97C1 |
BCL | Apoptosis |
Sabutoclax (BI-97C1) 是一种泛 Bcl-2 抑制剂,包括 Bcl-xL、Bcl-2、Mcl-1 和 Bfl-1,IC50 分别为 0.31 μM、0.32 μM、0.20 μM 和 0.62 μM。 | |||
T6275 |
Obatoclax Mesylate
Obatoclax,GX15-070,奥巴克拉甲磺酸盐 |
BCL; Parasite; Autophagy | Apoptosis; Autophagy; Microbiology/Virology |
Obatoclax Mesylate (GX15-070) 是泛 BCL-2家族蛋白抑制剂,对 BCL-2 的 Ki 值为 220 nM。它是 BH3 模拟物,具有抗癌和广谱抗寄生虫活性。它诱导自噬依赖性细胞死亡,并靶向细胞周期蛋白 D1 进行蛋白酶体降解。 | |||
T39910 |
Desmorpholinyl Navitoclax-NH-Me
Desmorpholinyl ABT-263-NH-Me,Desmorpholinyl Navitoclax-NH-Me |
BCL | Apoptosis |
Desmorpholinyl Navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) is a Bcl-xL inhibitor, which can be employed alongside a CRBN ligand to synthesize XZ739, a PROTAC BCL-XL degrader [1] [2]. | |||
T14213 |
Tapotoclax
AMG-176 |
BCL | Apoptosis |
AMG-176 is a MCL-1 inhibitor (Ki: 0.13 nM). | |||
T41278 | Obatoclax | ||
Obatoclax (GX15-070) 是一种 BH3 模拟物,是泛BCL-2家族蛋白抑制剂,对 BCL-2 的Ki 值为 220 nM。Obatoclax 诱导依赖自噬 (autophagy)的细胞死亡,并靶向细胞周期蛋白 D1 进行蛋白酶体降解。Obatoclax 具有抗癌和广谱抗寄生虫 (antiparasitic) 活性。 | |||
T27600 |
Imlatoclax
|
||
Imlatoclax has antineoplastic activity. | |||
T36901 |
Pelcitoclax
|
||
Pelcitoclax (APG-1252) is a powerful inhibitor of the Bcl-2 and Bcl-xl proteins, displaying significant antineoplastic and pro-apoptotic properties[1]. | |||
TMIH-0594 |
Venetoclax-d8
|
||
Venetoclax-d8 是 Venetoclax 的氘代化合物。 | |||
T74637 |
Sonrotoclax
|
||
Sonrotoclax为一种口服有效的Bcl2抑制剂,对多种淋巴瘤和白血病细胞系展现出显著的细胞杀伤能力。 | |||
T71456 |
Navitoclax dihydrochloride
|
||
Navitoclax dihydrochloride is a synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. | |||
T16694 |
Pyridoclax
MR-29072 |
BCL | Apoptosis |
Pyridoclax is an inhibitor of potential Mcl-1. | |||
T79852 |
Lacutoclax
|
||
Lacutoclax为Bcl-2抑制剂,展现出抗肿瘤活性。 | |||
T78638 |
Clezutoclax
|
||
Clezutoclax为Bcl-XL抑制剂且作为活性载体,可应用于抗体药物偶联物(ADC)的合成。 | |||
T22257 |
Murizatoclax
|
Others | Others |
AMG 397 is an oral MCL1 inhibitor . | |||
T74015 |
Venetoclax N-oxide
|
||
Venetoclax N-oxide 是 Venetoclax 的杂质。Venetoclax (ABT-199; GDC-0199) 是一种高效,选择性的和口服有效的Bcl-2抑制剂,Ki 小于0.01 nM。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01231 |
CLEC2D Protein, Human, Recombinant (hFc & Avi), Biotinylated
OCILmember D,LLT1,CLAX,CLEC2D,CLAXLLT-1,LL... |
Human | HEK293 Cells |
C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. | |||
TMPK-01230 |
CLEC2D Protein, Human, Recombinant (hFc & Avi)
Lectin-like NK cell receptor,LLT-1,OCIL,LLT1,Lectin-like tra... |
Human | HEK293 Cells |
C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. However, this implication may be confounded by highly active anti-retroviral treatment (HAART). |